Physician profile
Ron Zuiderweg
NPI 1386680387
$1,395.98
in general payments reported to CMS, 2019-2025
18 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.50 · 2020: $19.24 · 2021: $293 · 2022: $250 · 2023: $277 · 2024: $169 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $306.80 | 2020-2025 | Lokelma |
| Vifor Pharma, INC. | $185.63 | 2019-2024 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $184.84 | 2023-2025 | |
| Daiichi Sankyo INC. | $110.86 | 2021-2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $90.50 | 2019-2024 | Jynarque |
| Amgen INC. | $89.12 | 2022-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $82.86 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $71.24 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $49.49 | 2021-2024 | |
| Cormedix INC. | $39.03 | 2024 | Defencath |
| Glaxosmithkline, LLC. | $37.27 | 2022-2023 | Benlysta |
| Horizon Therapeutics Plc | $35.16 | 2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $28.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.51 | 2025 | Jardiance |
| Akebia Therapeutics INC | $19.85 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.65 | 2019 | |
| Fresenius USA Marketing, INC. | $16.01 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Zuiderweg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.